Highlights

  • Cleo Diagnostics outlined its U.S. reimbursement and commercialisation strategy ahead of anticipated FDA clearance.
  • CLEO plans to commercialise its ovarian cancer diagnostic test using CPT code 81599 immediately after FDA clearance.
  • Comparable ovarian cancer diagnostic assays have reported reimbursement levels of approximately US$500 to US$900 per test.
  • The strategy is designed to support early billing, clinical adoption and real-world evidence generation.
  • CLEO intends to later apply for a dedicated CPT code to support long-term reimbursement and commercial scaling.

Cleo Diagnostics Ltd (ASX:COV) shares traded modestly higher during the morning session on 20 May 2026 after the company announced a key step in its United States commercialisation strategy ahead of its anticipated Food and Drug Administration (FDA) submission.

The company revealed that it has established an initial reimbursement pathway for its pre-surgical ovarian cancer diagnostic test in the U.S., outlining plans to utilise the miscellaneous CPT code 81599 immediately following potential FDA clearance.

Although the share price increase during the session was relatively moderate at 0.79%, the update comes as investors continue to monitor the company’s progress toward commercialisation of its ovarian cancer diagnostic platform. Over the past year, Cleo Diagnostics shares have risen approximately 82.86%.

Company Overview

Cleo Diagnostics Ltd is an Australian medical technology company focused on the development of blood-based diagnostic tests for ovarian cancer detection.

The company’s lead programme centres on a pre-surgical ovarian cancer triage test designed to support earlier and more accurate diagnosis.

Cleo’s technology platform is based on the CXCL10 biomarker following more than 15 years of scientific Research and Development.

The company is currently progressing pivotal clinical trial activities ahead of anticipated FDA submission and future commercial launch activities in the United States.

U.S. Reimbursement Strategy Outlined Ahead of FDA Clearance

Cleo Diagnostics stated that the reimbursement framework is designed to support immediate market entry and early Revenue generation in the United States following anticipated FDA clearance of its pre-surgical ovarian cancer test.

Under the proposed strategy, the company intends to commercialise the test using existing miscellaneous CPT code 81599, a reimbursement pathway commonly used by novel diagnostic technologies entering the healthcare system.

According to the company, this approach is expected to allow early clinical adoption and collection of real-world utilisation data, which are considered important steps before applying for a dedicated reimbursement code.

Management indicated that reimbursement under CPT code 81599 is generally determined on a payer-by-payer basis using comparable diagnostic tests as reference points.

The company referenced existing multi-biomarker ovarian cancer assays, including OVA1, which have reported reimbursement levels ranging between approximately US$500 to US$900 per test depending on the payer.

Cleo Diagnostics stated that these existing benchmarks provide an initial framework for pricing and reimbursement discussions as commercialisation efforts progress.

Immediate Post-Clearance Commercialisation Targeted

The company described the use of CPT code 81599 as a significant commercialisation milestone because it would allow operations to commence immediately after FDA clearance.

According to Cleo Diagnostics, this pathway is expected to support several early-stage commercial objectives including revenue generation through case-by-case billing and expansion of clinical use across healthcare settings in the United States.

Management also noted that the reimbursement structure is expected to assist with pricing discussions involving both government and commercial healthcare payers.

In addition, the company plans to use the initial rollout phase to generate real-world clinical and economic evidence intended to demonstrate the value of its diagnostic platform.

Cleo Diagnostics believes that the collection of utilisation data through early commercial activity will help underpin future applications for a dedicated CPT code.

Dedicated CPT Code Remains Longer-Term Objective

While the miscellaneous CPT code forms the first stage of the company’s reimbursement strategy, Cleo Diagnostics confirmed that it ultimately intends to seek a dedicated CPT code through the American Medical Association CPT Editorial Panel.

Management stated that progression toward a dedicated reimbursement code is expected to occur after clinical utilisation and supporting evidence have been established.

According to the company, a dedicated CPT code could provide several longer-term commercial advantages including improved reimbursement consistency, broader payer coverage and more transparent utilisation tracking.

The company also indicated that a dedicated code could strengthen the long-term commercial positioning of its ovarian cancer diagnostic platform within the U.S. healthcare market.

Timeline for Reimbursement Progression Detailed

Cleo Diagnostics outlined an expected sequence for commercial and reimbursement milestones associated with the U.S. rollout strategy.

The company stated that use of miscellaneous CPT code 81599 is expected immediately after FDA clearance in order to support early billing, clinical adoption and evidence generation activities.

Following approximately six to twelve months of commercial utilisation, management intends to submit an application for a dedicated CPT code during the next available American Medical Association review cycle.

The company indicated that approval of a dedicated CPT code would support broader reimbursement adoption and scalability over time.

Market Access Activities Continue

Alongside reimbursement planning, Cleo Diagnostics confirmed that it is continuing to advance broader U.S. market access initiatives intended to support adoption of the test.

The company stated that ongoing activities include development of health Economics and budget impact models designed to support reimbursement discussions.

Management also noted that the company is onboarding key opinion leaders to support early clinical adoption and strengthen market engagement efforts.

Cleo Diagnostics additionally plans to generate real-world evidence through its initial commercial rollout programme.

According to the company, these activities are intended to complement data generated under the miscellaneous CPT reimbursement structure while supporting future transition toward a dedicated reimbursement code.

Focus on Ovarian Cancer Detection

Cleo Diagnostics is developing diagnostic technologies focused on ovarian cancer detection, an area where management says there remains significant unmet clinical need.

The company highlighted that ovarian cancer continues to have one of the highest five-year mortality rates among cancers affecting women, with many cases diagnosed only after the disease has progressed to later stages.

Cleo’s technology platform is based on the CXCL10 biomarker, which the company states is produced early and at elevated levels in ovarian cancer while remaining largely absent in benign disease.

Management believes this characteristic may help distinguish malignant from non-malignant growths.

The company’s commercial strategy currently centres on a pre-surgical triage test, with plans to later expand into recurrence monitoring and broader screening applications.

FDA Submission and Commercial Launch Remain Key Milestones

Cleo Diagnostics confirmed that it is currently conducting its pivotal clinical trial as part of the pathway toward FDA submission.

The company stated that FDA submission and commercial launch are expected next year.

The latest reimbursement announcement appears intended to demonstrate that commercial planning is progressing in parallel with regulatory activities.

For healthcare diagnostic companies, reimbursement strategy is often considered an important component of market adoption because successful commercial deployment typically depends on both regulatory clearance and payer support.

Investors Continue Monitoring Commercialisation Progress

Today’s market response suggests investors remain focused on Cleo Diagnostics’ commercialisation pathway as the company moves closer toward anticipated FDA-related milestones.

While the share price movement was relatively modest compared with some ASX biotechnology announcements, the reimbursement framework announcement provides additional detail around how the company intends to approach market entry in the United States.

The update also highlights the company’s broader focus on generating real-world evidence and establishing reimbursement structures that could support future scaling opportunities.

What This Means for Investors?

Cleo Diagnostics’ latest announcement outlines an important commercialisation and reimbursement framework ahead of anticipated FDA clearance for its ovarian cancer diagnostic test.

The company’s strategy to initially commercialise through miscellaneous CPT code 81599 is intended to support early billing, clinical adoption and real-world evidence generation while building toward a dedicated reimbursement code over time.

Investors are likely to continue monitoring progress relating to the pivotal clinical trial, future FDA submission milestones and the company’s broader U.S. market entry strategy.